Progestin-primed ovarian stimulation for oocyte cryopreservation in patients with nonmedical indications: a case–control study

Abstract Background The PPOS (Progestin Primed Ovarian Stimulation) protocol has been evaluated and has proved its effectiveness in preventing the LH (luteinizing hormone) surge. This protocol is often used for cryopreservation for social reasons because it is simpler and more cost-effective. The ob...

Full description

Saved in:
Bibliographic Details
Main Authors: Ophélie Sounigo, Léah Cohen Aloro, Michael Grynberg, Céleste Becquart, Maxence Majer, Vincent Puy, Christophe Sifer, Claire Vinolas, Florence Eustache, Laetita Hesters, Anne Mayeur, Isabelle Cedrin-Durnerin, Charlotte Sonigo, Maeliss Peigné
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Reproductive Biology and Endocrinology
Subjects:
Online Access:https://doi.org/10.1186/s12958-025-01402-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850278117447303168
author Ophélie Sounigo
Léah Cohen Aloro
Michael Grynberg
Céleste Becquart
Maxence Majer
Vincent Puy
Christophe Sifer
Claire Vinolas
Florence Eustache
Laetita Hesters
Anne Mayeur
Isabelle Cedrin-Durnerin
Charlotte Sonigo
Maeliss Peigné
author_facet Ophélie Sounigo
Léah Cohen Aloro
Michael Grynberg
Céleste Becquart
Maxence Majer
Vincent Puy
Christophe Sifer
Claire Vinolas
Florence Eustache
Laetita Hesters
Anne Mayeur
Isabelle Cedrin-Durnerin
Charlotte Sonigo
Maeliss Peigné
author_sort Ophélie Sounigo
collection DOAJ
description Abstract Background The PPOS (Progestin Primed Ovarian Stimulation) protocol has been evaluated and has proved its effectiveness in preventing the LH (luteinizing hormone) surge. This protocol is often used for cryopreservation for social reasons because it is simpler and more cost-effective. The objective of our study was to evaluate the efficacy and the convenience of the PPOS protocol in the context of oocyte cryopreservation for social reasons. Methods In this bicentric matched case‒control study, all PPOS cycles performed for nonmedical reasons between January 2021 and June 2023 were included. Each PPOS cycle was matched with 2 control cycles performed with the antagonist protocol on the basis of the antral follicle count (+/- 5), BMI (+/- 2 kg/cm2) and starting gonadotropin dose (+/- 75 UI). The primary endpoint was the number of mature oocytes. The secondary endpoints were other parameters and outcomes of COS. We evaluated the convenience of PPOS by analysing the frequency of monitoring sessions. Univariate analysis was performed via univariate conditional logistic regression. Multivariate analysis was performed via conditional multivariate logistic regression for significant parameters in the univariate analysis (p < 0.2). Results The patient characteristics were comparable, except the median age, which was lower in the antagonist group (35.5 vs. 34.6 years, p < 0.001). Multivariate analysis revealed no statistically significant difference in the number of metaphase II (MII) oocytes between the groups (p = 0.91) or in the total number of COCs retrieved (0.94). There was no statistically significant difference between the groups in terms of the maturation rate or the OSI (p = 0.38 and p = 0.16). The number of monitoring sessions was significantly lower in the PPOS protocol group (p < 0.001). Conclusion The response to ovarian stimulation with the PPOS protocol for oocyte cryopreservation in patients with nonmedical indications does not differ statistically from that with the antagonist protocol in terms of the number of MII oocytes. This protocol offers the advantages of a more patient-friendly approach through oral administration, a significantly lower number of monitoring sessions with the same efficacy as the antagonist protocol and could be offered as a first line treatment. Clinical trial number NA. Trial registration date NA.
format Article
id doaj-art-9d9f0146c87741cc8fd4b2b4cf7f4dfb
institution OA Journals
issn 1477-7827
language English
publishDate 2025-05-01
publisher BMC
record_format Article
series Reproductive Biology and Endocrinology
spelling doaj-art-9d9f0146c87741cc8fd4b2b4cf7f4dfb2025-08-20T01:49:38ZengBMCReproductive Biology and Endocrinology1477-78272025-05-0123111010.1186/s12958-025-01402-2Progestin-primed ovarian stimulation for oocyte cryopreservation in patients with nonmedical indications: a case–control studyOphélie Sounigo0Léah Cohen Aloro1Michael Grynberg2Céleste Becquart3Maxence Majer4Vincent Puy5Christophe Sifer6Claire Vinolas7Florence Eustache8Laetita Hesters9Anne Mayeur10Isabelle Cedrin-Durnerin11Charlotte Sonigo12Maeliss Peigné13Department of Reproductive Medicine and Fertility Preservation, Universite Sorbonne Paris Nord, Assistance Publique– Hopitaux de Paris, Jean Verdier HospitalDepartment of Reproductive Medicine and Fertility Preservation, Universite Sorbonne Paris Nord, Assistance Publique– Hopitaux de Paris, Jean Verdier HospitalDepartment of Reproductive Medicine and Fertility Preservation, Universite Sorbonne Paris Nord, Assistance Publique– Hopitaux de Paris, Jean Verdier HospitalDepartment of Reproductive Medicine and Fertility Preservation, Universite Paris-Saclay, Assistance Publique Hopitaux de Paris, Antoine Beclere HospitalDepartment of Reproductive Medicine and Fertility Preservation, Universite Sorbonne Paris Nord, Assistance Publique– Hopitaux de Paris, Jean Verdier HospitalDepartment of Biology of Reproduction, Universite Sorbonne Paris Nord, Assistance Publique– Hopitaux de Paris, Jean Verdier HospitalDepartment of Biology of Reproduction, Universite Sorbonne Paris Nord, Assistance Publique– Hopitaux de Paris, Jean Verdier HospitalDepartment of Reproductive Medicine and Fertility Preservation, Universite Sorbonne Paris Nord, Assistance Publique– Hopitaux de Paris, Jean Verdier HospitalCECOS, Universite Sorbonne Paris Nord, Assistance Publique– Hopitaux de Paris, Jean Verdier HospitalDepartment of Biology of Reproduction, Universite Paris-Saclay, Assistance Publique Hopitaux de Paris, Antoine Beclere HospitalDepartment of Biology of Reproduction, Universite Paris-Saclay, Assistance Publique Hopitaux de Paris, Antoine Beclere HospitalDepartment of Reproductive Medicine and Fertility Preservation, Universite Sorbonne Paris Nord, Assistance Publique– Hopitaux de Paris, Jean Verdier HospitalDepartment of Reproductive Medicine and Fertility Preservation, Universite Paris-Saclay, Assistance Publique Hopitaux de Paris, Antoine Beclere HospitalDepartment of Reproductive Medicine and Fertility Preservation, Universite Sorbonne Paris Nord, Assistance Publique– Hopitaux de Paris, Jean Verdier HospitalAbstract Background The PPOS (Progestin Primed Ovarian Stimulation) protocol has been evaluated and has proved its effectiveness in preventing the LH (luteinizing hormone) surge. This protocol is often used for cryopreservation for social reasons because it is simpler and more cost-effective. The objective of our study was to evaluate the efficacy and the convenience of the PPOS protocol in the context of oocyte cryopreservation for social reasons. Methods In this bicentric matched case‒control study, all PPOS cycles performed for nonmedical reasons between January 2021 and June 2023 were included. Each PPOS cycle was matched with 2 control cycles performed with the antagonist protocol on the basis of the antral follicle count (+/- 5), BMI (+/- 2 kg/cm2) and starting gonadotropin dose (+/- 75 UI). The primary endpoint was the number of mature oocytes. The secondary endpoints were other parameters and outcomes of COS. We evaluated the convenience of PPOS by analysing the frequency of monitoring sessions. Univariate analysis was performed via univariate conditional logistic regression. Multivariate analysis was performed via conditional multivariate logistic regression for significant parameters in the univariate analysis (p < 0.2). Results The patient characteristics were comparable, except the median age, which was lower in the antagonist group (35.5 vs. 34.6 years, p < 0.001). Multivariate analysis revealed no statistically significant difference in the number of metaphase II (MII) oocytes between the groups (p = 0.91) or in the total number of COCs retrieved (0.94). There was no statistically significant difference between the groups in terms of the maturation rate or the OSI (p = 0.38 and p = 0.16). The number of monitoring sessions was significantly lower in the PPOS protocol group (p < 0.001). Conclusion The response to ovarian stimulation with the PPOS protocol for oocyte cryopreservation in patients with nonmedical indications does not differ statistically from that with the antagonist protocol in terms of the number of MII oocytes. This protocol offers the advantages of a more patient-friendly approach through oral administration, a significantly lower number of monitoring sessions with the same efficacy as the antagonist protocol and could be offered as a first line treatment. Clinical trial number NA. Trial registration date NA.https://doi.org/10.1186/s12958-025-01402-2Social freezingFertility preservationDydrogesteroneProgestin-stimulated ovarian stimulationOvarian stimulation index
spellingShingle Ophélie Sounigo
Léah Cohen Aloro
Michael Grynberg
Céleste Becquart
Maxence Majer
Vincent Puy
Christophe Sifer
Claire Vinolas
Florence Eustache
Laetita Hesters
Anne Mayeur
Isabelle Cedrin-Durnerin
Charlotte Sonigo
Maeliss Peigné
Progestin-primed ovarian stimulation for oocyte cryopreservation in patients with nonmedical indications: a case–control study
Reproductive Biology and Endocrinology
Social freezing
Fertility preservation
Dydrogesterone
Progestin-stimulated ovarian stimulation
Ovarian stimulation index
title Progestin-primed ovarian stimulation for oocyte cryopreservation in patients with nonmedical indications: a case–control study
title_full Progestin-primed ovarian stimulation for oocyte cryopreservation in patients with nonmedical indications: a case–control study
title_fullStr Progestin-primed ovarian stimulation for oocyte cryopreservation in patients with nonmedical indications: a case–control study
title_full_unstemmed Progestin-primed ovarian stimulation for oocyte cryopreservation in patients with nonmedical indications: a case–control study
title_short Progestin-primed ovarian stimulation for oocyte cryopreservation in patients with nonmedical indications: a case–control study
title_sort progestin primed ovarian stimulation for oocyte cryopreservation in patients with nonmedical indications a case control study
topic Social freezing
Fertility preservation
Dydrogesterone
Progestin-stimulated ovarian stimulation
Ovarian stimulation index
url https://doi.org/10.1186/s12958-025-01402-2
work_keys_str_mv AT opheliesounigo progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT leahcohenaloro progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT michaelgrynberg progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT celestebecquart progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT maxencemajer progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT vincentpuy progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT christophesifer progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT clairevinolas progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT florenceeustache progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT laetitahesters progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT annemayeur progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT isabellecedrindurnerin progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT charlottesonigo progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy
AT maelisspeigne progestinprimedovarianstimulationforoocytecryopreservationinpatientswithnonmedicalindicationsacasecontrolstudy